ArticlePloS one2026
Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMASLD is linked to dyslipidemia, but it remains unclear whether this alteration depends more on disease activity or fibrosis.
objectiveTo determine whether dyslipidemia is primarily associated with activity and/or fibrosis through standard lipid profile and advanced lipidomics.
methodsA cross-sectional study was conducted including patients with suspected MASLD at a single center. Intraoperative liver biopsies were obtained. Only patients with MASLD were included in the analysis. Histological activity was defined as a NAFLD Activity Score (NAS) ≥5 and fibrosis was staged according to standard criteria. Clinical, biochemical, lipoprotein, and fatty acid profiles were assessed, including nuclear magnetic resonance (NMR) spectroscopy for lipoprotein subfractions and gas chromatography for fatty acids. Multivariable linear regression models were used to evaluate independent associations of activity and fibrosis with lipid parameters.
resultsA total of 49 patients were analyzed (mean age 48 years, 46% men, 94% with BMI > 35). Liver biopsies revealed a 30.6% prevalence of activity (NAS ≥ 5) and 36.7% of fibrosis. Higher lipid levels in patients with activity were related to apolipoprotein B, non-HDL cholesterol, and triglycerides in both univariate and multivariate models. Fibrosis was not associated with any lipid parameter. Lipidomics confirmed associations of activity with VLDL+IDL cholesterol (β = 0.474, 95% CI 0.204-0.745, p = 0.001), VLDL+IDL triglycerides (β = 0.454, 95% CI 0.198-0.710, p = 0.001), and VLDL particle concentration (β = 0.409, 95% CI 0.155-0.663, p = 0.002), and showed a trend toward an inverse association with the percentage of large VLDL particles (β=-0.298, 95% CI -0.602-0.006, p = 0.054). Besides, the omega-6/triglycerides ratio was inversely associated with activity (β=-0.345, 95% CI -0.630 to -0.060, p = 0.019).
conclusionHepatic inflammatory activity showed strong associations with a non-traditional atherogenic lipidomic profile. These findings suggest that activity, rather than liver fibrosis, may be a key factor in the MASLD atherosclerotic momentum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.